Myriad Genetics Stock Alpha and Beta Analysis
| MYGN Stock | USD 15.71 0.22 1.42% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Myriad Genetics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Myriad Genetics over a specified time horizon. Remember, high Myriad Genetics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Myriad Genetics' market risk premium analysis include:
Beta 0.61 | Alpha (0.90) | Risk 3.52 | Sharpe Ratio (0.24) | Expected Return (0.85) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Myriad |
Myriad Genetics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Myriad Genetics market risk premium is the additional return an investor will receive from holding Myriad Genetics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Myriad Genetics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Myriad Genetics' performance over market.| α | -0.9 | β | 0.61 |
Myriad Genetics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Myriad Genetics' Buy-and-hold return. Our buy-and-hold chart shows how Myriad Genetics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Myriad Genetics Market Price Analysis
Market price analysis indicators help investors to evaluate how Myriad Genetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Myriad Genetics shares will generate the highest return on investment. By understating and applying Myriad Genetics stock market price indicators, traders can identify Myriad Genetics position entry and exit signals to maximize returns.
Myriad Genetics Return and Market Media
The median price of Myriad Genetics for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 25.1 with a coefficient of variation of 19.61. The daily time series for the period is distributed with a sample standard deviation of 4.57, arithmetic mean of 23.31, and mean deviation of 3.89. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Insider Trading | 09/03/2024 |
2 | Disposition of 964 shares by Natalie Munk of Myriad Genetics at 27.64 subject to Rule 16b-3 | 09/20/2024 |
3 | Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer | 10/08/2024 |
4 | OmniStar Financial Group Inc. Makes New 863,000 Investment in Myriad Genetics, Inc. | 10/18/2024 |
5 | Disposition of 2231 shares by Ancona Margaret of Myriad Genetics at 22.72 subject to Rule 16b-3 | 10/22/2024 |
6 | Myriad Genetics Reports Third Quarter 2024 Financial Results Updates 2024 Financial Guidance | 11/07/2024 |
7 | Myriad Genetics Inc Q3 2024 Earnings Call Highlights Strong Revenue Growth Amid Policy ... | 11/08/2024 |
8 | Myriad Genetics, Inc. Investigation Ongoing Contact Levi Korsinsky About Potential Securities Fraud Allegations - MYGN | 11/11/2024 |
9 | Myriad Genetics Inc Shares Gap Down to 16.76 on Nov 12 | 11/12/2024 |
10 | Shareholders that Lost Money on Myriad Genetics, Inc. Should Contact Levi Korsinsky about Securities Fraud Investigation - MYGN | 11/13/2024 |
11 | Myriad Genetics, Inc. Being Investigated on Behalf of Myriad Genetics, Inc. Investors. Contact Levi Korsinsky For Details | 11/14/2024 |
12 | Stock Analysis Myriad Uranium Corp. | 11/15/2024 |
13 | Myriad Genetics, Inc. INVESTIGATION Levi Korsinsky Investigates Potential Securities Fraud by Myriad Genetics, Inc. | 11/18/2024 |
14 | Myriad Genetics price target lowered to 21 from 32 at Morgan Stanley | 11/19/2024 |
15 | MYGN Stock Up on Integration of HRD Platform Into Illuminas TSO 500 v2 | 11/25/2024 |
About Myriad Genetics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Myriad or other stocks. Alpha measures the amount that position in Myriad Genetics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 0.37 | 0.22 | Price To Sales Ratio | 1.98 | 1.88 |
Myriad Genetics Upcoming Company Events
As portrayed in its financial statements, the presentation of Myriad Genetics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Myriad Genetics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Myriad Genetics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Myriad Genetics. Please utilize our Beneish M Score to check the likelihood of Myriad Genetics' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Myriad Genetics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Myriad Genetics Backtesting, Myriad Genetics Valuation, Myriad Genetics Correlation, Myriad Genetics Hype Analysis, Myriad Genetics Volatility, Myriad Genetics History and analyze Myriad Genetics Performance. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Myriad Genetics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.